1366438441
Not So Different: A Podcast from The Center for Biosimilars

Advertise on podcast: Not So Different: A Podcast from The Center for Biosimilars

Rating
★★★★★
5
from
7 reviews
This podcast has
158 episodes
Language
English
Date created
2018/03/30
Latest episode
2025/11/30
Average duration
16 min.
Release period
37 days

Description

"Not So Different," a podcast from The Center for Biosimilars, brings you expert viewpoints from physicians, pharmacists, patients, developers, and other stakeholders in the complex world of biosimilar therapies.

Unlock Not So Different: A Podcast from The Center for Biosimilars podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Not So Different: A Podcast from The Center for Biosimilars podcast


All Things Biosimilars: How Streamlined CES Rules Could Shift the Market
2025/11/30
To learn more about the FDA draft guidance regarding clinical efficacy studies for biosimilars and interchangeability, click here.To read more about G's discussion with Sarah Yim, MD, from the FDA from the recent 2025 GRx+Biosims conference, click here.To read more on Yim's perspectives on biosimilar policy harmonization, click here.
Follow the Science: Bridging the Biosimilar Gap
2025/07/27
This special vodcast series provided by The Center for Biosimilars® was developed in partnership with the AAM and Biosimilars Council. Check out part 1 of the series featuring a discussion between Giuseppe Randazzo and Craig Burton, former executive director of the Biosimilars Council and current senior vice president of government affairs and policy at Fresenius Kabi.ReferencesJeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars
Escaping the Void: All Things Biosimilars With Craig & G
2025/05/05
REFERENCEJeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
2025/03/09
Show notes To learn more about the 10th anniversary of the first FDA biosimilar approval, click here. To learn more about how much biosimilars have saved so far, click here. To read more about Josh's views on the pharmaceutical landscape in 2025, click here.
Will the FTC Be More PBM-Friendly Under A Second Trump Administration?
2025/02/23
Show notes To learn more about the FTC's most recent report on PBMs, click here. To learn more about the FTC's first report on PBMs, click here. To learn more about health care actions taken by the second Trump Administration during it's first month, click here. To learn more about the views of Mehmet Oz, MD (more commonly known as Dr. Oz) on price transparency ahead of his congressional confirmation hearings as President Trump's nominee for HHS Secretary, click here.
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
2025/02/09
Show notes1. Jeremias S. A banner year for biosimilars: The 19 FDA approvals from 2024. The Center for Biosimilars. January 21, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/a-banner-year-for-biosimilars-the-18-fda-approvals-from-2024 2. Jeremias S. FDA approves Celltrion's Avtozma as third tocilizumab biosimilar. The Center for Biosimilars. January 31, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/fda-approves-celltrion-s-avtozma-as-third-tocilizumab-biosimilar 3. Jeremias S. Senators introduce bipartisan legislation to protect skinny labeling. The Center for Biosimilars. January 2, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/senators-introduce-bipartisan-legislation-to-protect-skinny-labeling 4. Jeremias S. FTC releases second report on PBMs meddling in generic drug markets. The Center for Biosimilars. January 19, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/ftc-releases-second-report-on-pbms-meddling-in-generic-drug-markets 5. Santoro C. Earlier patent litigation could accelerate US biosimilar market entry. The Center for Biosimilars. January 9, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/earlier-patent-litigation-could-accelerate-us-biosimilar-market-entry 6. Jeremias S. Welcome Wezlana: the first Stelara biosimilar to launch in the US. The Center for Biosimilars. January 31, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/welcome-wezlana-the-first-stelara-biosimilar-to-launch-in-the-us 7. Jeremias S, Chambers JD. The banking of biosimilars: insights from a leading health economist. The Center for Biosimilars. February 4, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/the-banking-of-biosimilars-insights-from-a-leading-health-economist 8. Jeremias S. The biosimilar void: 90% of biologics coming off patent will lack biosimilars. The Center for Biosimilars. February 5, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars 9. Jeremias S. Biosimilars drive cost savings and achieve 53% market share across treatment areas. The Center for Biosimilars. January 16, 2025. Accessed February 7, 2025. https://www.centerforbiosimilars.com/view/biosimilars-drive-cost-savings-and-achieve-53-market-share-across-treatment-areas
The Top 5 Most-Listened to Podcasts of 2024
2024/12/29
Here are the top 5 episodes of Not So Different from 2024. Number 5: Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti ApprovedNumber 4: Decoding the Patent Puzzle: Navigating the Legal Landscape of BiosimilarsNumber 3: Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar ReportNumber 2: Biosimilars in America: Overcoming Barriers and Maximizing ImpactNumber 1: Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
2024/12/01
Show Notes 1. Jeremias S. Skyrizi overtakes Humira: “product hopping” leaves biosimilar market in limbo. The Center for Biosimilars. November 7, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/skyrizi-overtakes-humira-product-hopping-leaves-biosimilar-market-in-limbo 2. Jeremias S. Celltrion sets sights on 2030 with expanded biosimilar portfolio, market reach. The Center for Biosimilars. November 6, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/celltrion-sets-sights-on-2030-with-expanded-biosimilar-portfolio-market-reach 3. Ferreri D. Making the cost of IBD care sustainable. The Center for Biosimilars. November 2, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/making-the-cost-of-ibd-care-sustainable 4. Ferreri D. Achieving PFS in advanced gastric cancer with HLX02 biosimilar, chemotherapy. The Center for Biosimilars. November 23, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/achieving-pfs-in-advanced-gastric-cancer-with-hlx02-biosimilar-chemotherapy 5. Ferreri D. Subcutaneous infliximab CT-P13 superior to placebo as maintenance therapy for IBD. The Center for Biosimilars. November 16, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/subcutaneous-infliximab-ct-p13-superior-to-placebo-as-maintenance-therapy-for-ibd 6. Ferreri D. Challenges, obstacles, and future directions for anti-TNF biosimilars in IBD. The Center for Biosimilars.November 9, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/challenges-obstacles-and-future-directions-for-anti-tnf-biosimilars-in-ibd 7. Jeremias S. Breaking down biosimilar barriers: the patent system.The Center for Biosimilars. November 11, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-the-patent-system 8. Jeremias S. Breaking down biosimilar barriers: payer and PBM policies. The Center for Biosimilars. November 13, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-payer-and-pbm-policies 9. Poore D. Breaking down biosimilar barriers: interchangeability. The Center for Biosimilars. November 14, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/breaking-down-biosimilar-barriers-interchangeability 10. The Center for Biosimilars Staff. Webinar: streamlining the regulatory process to advance access to biosimilars. The Center for Biosimilars. November 21, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/webinar-streamlining-the-regulatory-process-to-advance-access-to-biosimilars 11. Jeremias S. Can global policies to boost biosimilar adoption work in the US? The Center for Biosimilars. November 17, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/can-global-policies-to-boost-biosimilar-adoption-work-in-the-us-
Can Global Policies to Boost Biosimilar Adoption Work in the US?
2024/11/17
Show notes To learn more about GBW, click here.To check out our coverage of the recent GRx+Biosims conference Craig mentioned, click here.To learn more about product hopping, click here. To read part 1 of our GBW series, click here.To read part 2 of our GBW series, click here.To read part 3 of our GBW series, click here.To hear another episode featuring more of Craig's thoughts on the Biden's administration's impact on the biosimilar industry, click here.
Biosimilars Development Roundup for October 2024—Podcast Edition
2024/11/03
Show notes 1. Jeremias S. Strengthening the supply chain: key insights from FDA commissioner Dr Robert Califf. The Center for Biosimilars®. October 25, 2024. Accessed November 1, 2024.  https://www.centerforbiosimilars.com/view/strengthening-the-supply-chain-key-insights-from-fda-commissioner-robert-califf 2. Jeremias S. FDA and industry experts unpack biosimilar device requirements. The Center for Biosimilars. October 23, 2024. Accessed November 1, 2024.  https://www.centerforbiosimilars.com/view/fda-and-industry-experts-unpack-biosimilar-device-requirements 3. Jeremias S. Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims. The Center for Biosimilars. October 23, 2024. Accessed November 1, 2024.  https://www.centerforbiosimilars.com/view/calling-for-unified-biosimilar-standards-stronger-education-at-grx-biosims 4. Jeremias S. Unifying standards: the need for streamlined biosimilar development. The Center for Biosimilars. October 22, 2024. Accessed November 1, 2024.  https://www.centerforbiosimilars.com/view/unifying-standards-the-need-for-streamlined-biosimilar-development 5. Jeremias S. Enhancing Adoption of Infused Biosimilars for a Sustainable Future. The Center for Biosimilars. October 30, 2024. Accessed November 1, 2024.  https://www.centerforbiosimilars.com/view/enhancing-adoption-of-infused-biosimilars-for-a-sustainable-future 6. Jeremias S. IQVIA webinar: enhancing regulatory strategies for biosimilars and generics. The Center for Biosimilars. October 14, 2024. Accessed November 1, 2024.  https://www.centerforbiosimilars.com/view/iqvia-webinar-enhancing-regulatory-strategies-for-biosimilars-and-generics
Biosimilars Policy Roundup for September 2024—Podcast Edition
2024/10/06
Show notes 1. FDA Approves Pavblu for Retinal Conditions2. AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 13. Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys4. The Future of Biosimilar Gene Therapies: Key Issues and Potential5. IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share6. The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings7. France Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD
Biosimilars Business Roundup for August 2024—Podcast Edition
2024/09/01
Show notes 1. Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 20242. Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 20243. Formycon Reports €26.9 Million Revenue for First Half 2024, Driven by Biosimilars4. CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel5. FDA Approves Biosimilar Enzeevu for Eye Conditions6. Manitoba Adopts Biosimilar Switching Policy7. Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results8. Vizient Report Projects Price Inflation for Originators With Biosimilars in the Pipeline
Biosimilars Policy Roundup for July 2024—Podcast Edition
2024/08/04
Show notes 1. FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara2. Ahzantive Receives FDA Approval as New Eylea Biosimilar3. FDA Approves Epysqli as Second Soliris Biosimilar4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed5. Biosimilars and Employers: Strategies for Success6. Learning the Lingo of Biologics and Biosimilars Is Critical7. Singapore Experience Shows Benefits of Value-Driven Strategies in Generating Biosimilar Savings8. Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
Biosimilars in America: Overcoming Barriers and Maximizing Impact
2024/07/21
Show notes To learn more about Cencora and their efforts, click here.To learn more about the Inflation Reduction Act's impact on biosimilars, click here.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
2024/07/07
Show notes 1. Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology3. EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions4. New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers5. ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars6. ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars7. Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability8. Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity

Podcast reviews

Read Not So Different: A Podcast from The Center for Biosimilars podcast reviews


5 out of 5
7 reviews
★★★★★
Rheumprov 2019/09/05
Great content! Critically important topic.
I have enjoyed this content. Biosimilars are critical to reducing cost and improving access to care for patients. This podcast offers multifaceted cov...
check all reviews on apple podcasts

Podcast sponsorship advertising

Start advertising on Not So Different: A Podcast from The Center for Biosimilars relevant audience podcasts


What do you want to promote?